Ozempic remains on top in the GLP-1 drug market -- but for how long?The anti-obesity drug market could one day be worth $100 billion. It's a massive opportunity in healthcare, and two companies that are leaders in that space today are Eli Lilly (LLY 0.23%) and Novo Nordisk (NVO 1.42%). Unsurprisingly, these are also two of the most valuable healthcare companies in the world right now.They have been rivals for decades, and the growing popularity of their respective glucagon-like peptide 1 (GLP-1) drugs ensur ...